Does cyclosporine preserve the anergic state of human T cells induced by costimulation blockade in vitro?
Timing and choice of conventional drug are crucial in the success of costimulation blockade-based tolerance induction therapies.
Our data suggest that tigecycline may be a promising drug with novel pharmacotherapeutic characteristics for the treatment of mild-to-severe AUD in both sexes.